drugset / Trial / NCT07670884

A Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Tablets in Overweight or Obese Subjects

NCT07670884

Phase 3 Not yet recruiting 425 enrolled Fujian Shengdi Pharmaceutical Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study aims to evaluate the efficacy and safety of HRS9531 tablets compared with placebo in reducing body weight in overweight or obese subjects after 52 weeks of treatment.

Timeline

Start
2026-07
Primary completion
2027-07
Completion
2027-08

Drugs

EvaluationDrugModalityDoseRoute
Subject HRS9531 Unknown

Indications

No indication recorded.